Famotidine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317862

CAS#: 76824-35-6

Description: Famotidine is a histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. Unlike cimetidine, the first H2 antagonist, Famotidine has no effect on the cytochrome P450 enzyme system and does not appear to interact with other drugs.


Chemical Structure

img
Famotidine
CAS# 76824-35-6

Theoretical Analysis

MedKoo Cat#: 317862
Name: Famotidine
CAS#: 76824-35-6
Chemical Formula: C8H15N7O2S3
Exact Mass: 337.0449
Molecular Weight: 337.45
Elemental Analysis: C, 28.47; H, 4.48; N, 29.06; O, 9.48; S, 28.51

Price and Availability

Size Price Availability Quantity
200.0mg USD 150.0 Same day
500.0mg USD 250.0 Same day
1.0g USD 450.0 Same day
5.0g USD 650.0 Same day
10.0g USD 950.0 Same day
50.0g USD 1950.0 2 weeks
Bulk inquiry

Synonym: Famotidine, Famotidine Hydrochloride, MK-208, Pepcid, YM-11170, YM11170, YM 11170, MK 208, MK208

IUPAC/Chemical Name: (Z)-3-(((2-((diaminomethylene)amino)thiazol-4-yl)methyl)thio)-N'-sulfamoylpropanimidamide

InChi Key: XUFQPHANEAPEMJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

SMILES Code: N/C(N)=N\C1=NC(CSCC/C(N)=N/S(=O)(N)=O)=CS1

Appearance: White to off-white solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Certificate of Analysis:

Safety Data Sheet (SDS):

Preparing Stock Solutions

The following data is based on the product molecular weight 337.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lin SY. An overview of famotidine polymorphs: solid-state characteristics, thermodynamics, polymorphic transformation and quality control. Pharm Res. 2014 Jul;31(7):1619-31. doi: 10.1007/s11095-014-1323-5. Epub 2014 Mar 1. Review. PubMed PMID: 24577998.

2: Deeks ED. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013 Sep;33(9):689-97. doi: 10.1007/s40261-013-0113-x. Review. PubMed PMID: 23881568.

3: Schiff M, Peura D. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012 Feb;6(1):25-35. doi: 10.1586/egh.11.88. Review. PubMed PMID: 22149579.

4: Tyre CC, Quan W. Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. Clin J Oncol Nurs. 2007 Aug;11(4):513-9. Review. PubMed PMID: 17723964.

5: Martinez MC. Famotidine in the management of schizophrenia. Ann Pharmacother. 1999 Jun;33(6):742-7. Review. PubMed PMID: 10410190.

6: James LP, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet. 1996 Aug;31(2):103-10. Review. PubMed PMID: 8853932.

7: Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther. 1996 Jan-Feb;18(1):36-54; discussion 35. Review. PubMed PMID: 8851452.

8: Golochevskaia VS. [Clinical aspects of Kvamatel (famotidine) administration]. Klin Med (Mosk). 1996;74(1):45-7. Review. Russian. PubMed PMID: 8649009.

9: Lengyel G, Fehér J. [Famotidine in the treatment of gastroduodenal ulcer]. Orv Hetil. 1994 Oct 16;135(42):2299-304. Review. Hungarian. PubMed PMID: 7970643.

10: Guimaraens D, Gonzales MA, Condé-Salazar L. Occupational allergic contact dermatitis from intermediate products in famotidine synthesis. Contact Dermatitis. 1994 Oct;31(4):259-60. Review. PubMed PMID: 7842684.

11: Yoshimoto K, Saima S, Echizen H, Nakamura Y, Kondo T, Yagishita Y, Ishizaki T. Famotidine-associated central nervous system reactions and plasma and cerebrospinal drug concentrations in neurosurgical patients with renal failure. Clin Pharmacol Ther. 1994 Jun;55(6):693-700. Review. PubMed PMID: 8004885.

12: Wesdorp IC. Famotidine in gastroesophageal reflux disease (GERD). Hepatogastroenterology. 1992 Feb;39 Suppl 1:24-6. Review. PubMed PMID: 1577391.

13: Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991 Sep;21(3):178-94. Review. PubMed PMID: 1764869.

14: Grigor'ev PIa, Isakov VA, Iakovenko EP, Davydov SM, Vasil'eva ZI. [Famotidine--a new histamine H2 receptor blockader]. Klin Med (Mosk). 1991 Apr;69(4):23-8. Review. Russian. PubMed PMID: 1865643.

15: Dammann HG. Clinical efficacy of famotidine in the treatment of acid-related diseases: an overview. Hepatogastroenterology. 1990 Jul;37 Suppl 1:2-5. Review. PubMed PMID: 2210612.

16: Langtry HD, Grant SM, Goa KL. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Oct;38(4):551-90. Review. PubMed PMID: 2573505.

17: Gitnick G. Famotidine in the USA: a review of efficacy studies. J Int Med Res. 1989;17 Suppl 1:17A-24A. Review. PubMed PMID: 2566539.

18: Berardi RR, Tankanow RM, Nostrant TT. Comparison of famotidine with cimetidine and ranitidine. Clin Pharm. 1988 Apr;7(4):271-84. Review. PubMed PMID: 2896559.

19: Mann SG. The place of famotidine in anti-ulcer therapy. Aliment Pharmacol Ther. 1987;1 Suppl 1:504S-509S. Review. PubMed PMID: 2979698.

20: Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987;134:55-60. Review. PubMed PMID: 2889260.

Famotidine

200.0mg / USD 150.0